Dexcom Reports Third Quarter 2024 Financial Results

Rhea-AI Summary

DexCom (DXCM) reported Q3 2024 financial results with revenue growing 2% year-over-year to $994.2 million. U.S. revenue declined 2% while international revenue grew 12%. GAAP operating income was $152.0 million (15.3% of revenue), showing a 580 basis points decrease compared to Q3 2023. The company launched Stelo, the first over-the-counter glucose biosensor in the U.S. for adults with prediabetes and type 2 diabetes not on insulin therapy. DexCom reiterated its 2024 guidance with expected revenue of $4.00-4.05 billion and announced the retirement of Chief Commercial Officer Teri Lawver at year-end.

Positive

• International revenue growth of 12% (16% organic)
• Launch of Stelo as first OTC glucose biosensor in U.S.
• Strong cash position of $2.49 billion
• Maintained 2024 revenue guidance of $4.00-4.05 billion (11-13% organic growth)

Negative

• U.S. revenue declined 2% year-over-year
• GAAP operating margin decreased 580 basis points to 15.3%
• Non-GAAP operating margin fell 320 basis points to 21.3%
• GAAP gross profit margin declined to 59.7% from 63.9%

Insights

Financial Analyst

Dexcom's Q3 results show concerning trends with revenue growth slowing to just 2% YoY at $994.2M. The U.S. market declined 2% while international growth of 12% provided some offset. Margins deteriorated significantly - GAAP operating margin fell 580 basis points to 15.3%, while non-GAAP operating margin dropped 320 basis points to 21.3%.

The $750M share repurchase program and maintained full-year guidance suggest management confidence, but execution challenges are evident. The launch of Stelo for the non-insulin T2D market represents a major expansion opportunity, though near-term growth headwinds persist. The unexpected retirement of the CCO adds another layer of uncertainty during this critical period.

Market Research Analyst

The slowdown in U.S. market performance is particularly concerning given it's Dexcom's core market. However, the company's strategic initiatives show promise:

• The Stelo launch opens up the massive prediabetes/T2D non-insulin market
• International expansion continues with new G7 and ONE+ launches
• The 15-day G7 system under FDA review could improve competitive positioning

The maintained guidance of 11-13% organic growth implies significant acceleration needed in Q4, which appears ambitious given current trajectory and competitive dynamics.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights:

• Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic¹ basis.
• U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic¹ basis, all on a year-over-year basis.
• GAAP operating income of $152.0 million or 15.3% of revenue, a decrease of 580 basis points compared to the third quarter of 2023. Non-GAAP operating income* of $212.0 million or 21.3% of reported revenue, a decrease of 320 basis points compared to the third quarter of 2023.

Third Quarter 2024 Strategic Highlights:

• Launched Stelo, Dexcom’s new biosensor designed for adults with prediabetes and type 2 diabetes who are not on insulin therapy, as the first over-the-counter glucose biosensor in the U.S.
• Advanced international product portfolio with the launches of Dexcom G7 in Australia and Dexcom ONE+ in France
• Executed $750 million share repurchase program, in-line with strategy discussed on the company’s second quarter earnings call
• Subsequent to the end of the quarter, submitted Dexcom G7 15-day CGM system to the FDA for review

“Dexcom’s third quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier this year,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “We made significant progress over the quarter to drive improved execution, leaving the company on track to continue on our momentum in the fourth quarter and into 2025.”

2024 Annual Guidance

Dexcom is reiterating fiscal year 2024 guidance for Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels:

• Revenue of approximately $4.00 - 4.05 billion (11 - 13% organic growth²)
• Non-GAAP Gross Profit Margin of approximately 63%
• Non-GAAP Operating Margin of approximately 20%
• Adjusted EBITDA Margin of approximately 29%

_________________________
1		Third quarter 2024 organic revenue was $994.7 million and excludes $0.5 million of foreign exchange impact. Third quarter 2023 reported revenue included $8.0 million of non-CGM revenue subsequently divested in the following twelve months.
2		Organic growth excludes non-CGM revenue acquired or divested in the trailing twelve months, as well as the impact of foreign exchange. Dexcom's 2024 organic growth expectation excludes approximately $30 million of fiscal year 2023 revenue related to the divestiture of certain non-CGM assets.

Commercial Leadership Update

Dexcom also announced today that Teri Lawver, Executive Vice President and Chief Commercial Officer, will retire at the end of the year. She will continue as a special advisor to Dexcom through early 2025 and Kevin Sayer, chairman, president and CEO, will assume leadership of the commercial organization as the company conducts a global search for a new chief commercial officer.

“I want to personally thank Teri for her strong leadership and dedication, as seen most clearly through the successful launches of G7 and Stelo,” said Kevin Sayer. “I look forward to guiding us through this transition phase as we capitalize on the incredible opportunity ahead.”

Third Quarter 2024 Financial Results

Revenue: In the third quarter of 2024, worldwide revenue grew 2% to $994.2 million on a reported basis, up from $975.0 million in the third quarter of 2023.

Gross Profit: GAAP gross profit totaled $593.8 million or 59.7% of revenue for the third quarter of 2024, compared to $623.3 million or 63.9% of revenue in the third quarter of 2023.

Non-GAAP gross profit* totaled $625.9 million or 63.0% of reported revenue for the third quarter of 2024, compared to $630.4 million or 64.7% of reported revenue in the third quarter of 2023.

Operating Income: GAAP operating income for the third quarter of 2024 was $152.0 million or 15.3% of revenue, compared to GAAP operating income of $205.5 million or 21.1% of revenue for the third quarter of 2023.

Non-GAAP operating income* for the third quarter of 2024 was $212.0 million or 21.3% of reported revenue, compared to non-GAAP operating income of $238.9 million or 24.5% of reported revenue for the third quarter of 2023.

Net Income and Diluted Net Income Per Share: GAAP net income was $134.6 million, or $0.34 per diluted share, for the third quarter of 2024, compared to GAAP net income of $120.7 million, or $0.29 per diluted share, for the third quarter of 2023.

Non-GAAP net income* was $179.9 million, or $0.45 per diluted share, for the third quarter of 2024, compared to non-GAAP net income of $202.8 million, or $0.50 per diluted share, for the third quarter of 2023. The third quarter 2024 non-GAAP net income excludes $8.3 million of amortization of intangible assets, $26.0 million of business transition and other significant items, $25.7 million of intellectual property litigation costs, $0.4 million of income from equity investments, and $14.3 million of tax adjustments.

Cash and Liquidity: As of September 30, 2024, Dexcom held $2.49 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities.

* See Table E below for a reconciliation of these GAAP and non-GAAP financial measures.

Conference Call

Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. To listen to the conference call, please dial (877) 344-3040 (U.S./Canada) or (646) 475-1647 (International) and use the confirmation ID “9430114” approximately five minutes prior to the start time.

Statement Regarding Use of Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), please see the section titled “About Non-GAAP Financial Measures” below as well as the related Table E. We have not reconciled our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates for fiscal year 2024 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, reconciliations of our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates are not available without unreasonable effort.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Category: IR

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s future operating results and financial position, including estimated Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin for fiscal year 2024, and expected growth rates as compared to the year ended December 31, 2023; future expenses and investments; and potential business opportunities. All forward-looking statements included in this press release are made as of the date of this press release, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and are therefore subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings filed with the Securities and Exchange Commission. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this communication or to conform these forward-looking statements to actual results.

DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data)
	September 30, 2024				December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	621.2			$	566.3
Short-term marketable securities		1,871.1				2,157.8
Accounts receivable, net		1,002.0				973.9
Inventory		586.3				559.6
Prepaid and other current assets		182.2				168.3
Total current assets		4,262.8				4,425.9
Property and equipment, net		1,318.8				1,113.1
Operating lease right-of-use assets		67.5				71.4
Goodwill		23.8				25.2
Intangibles, net		106.2				134.5
Deferred tax assets		486.5				419.4
Other assets		88.2				75.0
Total assets	$	6,353.8			$	6,264.5
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$	1,592.5			$	1,345.5
Accrued payroll and related expenses		105.8				171.0
Short-term operating lease liabilities		22.3				21.1
Deferred revenue		13.9				18.4
Total current liabilities		1,734.5				1,556.0
Long-term senior convertible notes		2,439.6				2,434.2
Long-term operating lease liabilities		71.1				80.1
Other long-term liabilities		129.6				125.6
Total liabilities		4,374.8				4,195.9
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023		—				—
Common stock, $0.001 par value, 800.0 million shares authorized; 408.8 million and 390.6 million shares issued and outstanding, respectively, at September 30, 2024; and 407.2 million and 385.4 million shares issued and outstanding, respectively, at December 31, 2023		0.4				0.4
Additional paid-in capital		2,050.5				3,514.6
Accumulated other comprehensive income (loss)		63.4				(16.7	)
Retained earnings		1,445.9				1,021.4
Treasury stock, at cost; 18.2 million shares at September 30, 2024 and 21.8 million shares at December 31, 2023		(1,581.2	)			(2,451.1	)
Total stockholders’ equity		1,979.0				2,068.6
Total liabilities and stockholders’ equity	$	6,353.8			$	6,264.5

DexCom, Inc. Table B Consolidated Statements of Operations (In millions, except per share data)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Revenue	$	994.2		$	975.0		$	2,919.5		$	2,587.8
Cost of sales		400.4			351.7			1,137.1			955.5
Gross profit		593.8			623.3			1,782.4			1,632.3
Operating expenses:
Research and development		135.4			131.4			412.9			369.7
Selling, general and administrative		306.4			286.4			958.4			881.8
Total operating expenses		441.8			417.8			1,371.3			1,251.5
Operating income		152.0			205.5			411.1			380.8
Other income (expense), net		25.4			34.9			86.6			83.4
Income before income taxes		177.4			240.4			497.7			464.2
Income tax expense		42.8			119.7			73.2			179.0
Net income	$	134.6		$	120.7		$	424.5		$	285.2
Basic net income per share	$	0.34		$	0.31		$	1.08		$	0.74
Shares used to compute basic net income per share		394.2			386.6			394.6			386.7
Diluted net income per share	$	0.34		$	0.29		$	1.04		$	0.69
Shares used to compute diluted net income per share		410.2			426.8			414.7			428.3

DexCom, Inc. Table C Revenue by Geography (Dollars in millions) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2024				2023				2024				2023
U.S. revenue	$	701.9			$	713.6			$	2,087.0			$	1,856.2
Year over year growth		(2	)%			24	%			12	%			21	%
% of total revenue		71	%			73	%			71	%			72	%
International revenue	$	292.3			$	261.4			$	832.5			$	731.6
Year over year growth		12	%			33	%			14	%			31	%
% of total revenue		29	%			27	%			29	%			28	%
Total revenue (1)	$	994.2			$	975.0			$	2,919.5			$	2,587.8
Year over year growth		2	%			27	%			13	%			24	%

(1)

The sum of the revenue components may not equal total revenue due to rounding.

DexCom, Inc. Table D Revenue by Component (Dollars in millions) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2024				2023				2024				2023
Sensor and other revenue (1) (2)	$	951.8			$	873.8			$	2,753.1			$	2,303.7
Year over year growth		9	%			31	%			20	%			27	%
% of total revenue		96	%			90	%			94	%			89	%
Hardware revenue (1) (3)	$	42.4			$	101.2			$	166.4			$	284.1
Year over year growth		(58	)%			(2	)%			(41	)%			(1	)%
% of total revenue		4	%			10	%			6	%			11	%
Total revenue (4)	$	994.2			$	975.0			$	2,919.5			$	2,587.8
Year over year growth		2	%			27	%			13	%			24	%

(1)		Includes allocated subscription revenue.
(2)		Includes services, freight, accessories, non-CGM revenue, etc.
(3)		Includes transmitter and receiver revenue.
(4)		The sum of the revenue components may not equal total revenue due to rounding.

DexCom, Inc. Table E Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures (In millions, except per share data) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2024				2023				2024				2023
GAAP gross profit	$	593.8			$	623.3			$	1,782.4			$	1,632.3
Amortization of intangible assets (1)		7.1				7.1				21.4				21.4
Business transition and other significant items (2)		25.0				—				32.3				—
Credits related to COVID-19 (3)		—				—				(3.0	)			—
Non-GAAP gross profit	$	625.9			$	630.4			$	1,833.1			$	1,653.7
GAAP operating income	$	152.0			$	205.5			$	411.1			$	380.8
Amortization of intangible assets (1)		8.3				8.8				27.1				26.6
Business transition and other significant items (2)		26.0				1.1				39.4				2.9
Credits related to COVID-19 (3)		—				—				(3.2	)			—
Intellectual property litigation costs (4)		25.7				23.5				73.2				65.6
Non-GAAP operating income	$	212.0			$	238.9			$	547.6			$	475.9
GAAP net income	$	134.6			$	120.7			$	424.5			$	285.2
Business transition and other significant items (2)		26.0				1.0				39.2				2.6
Credits related to COVID-19 (3)		—				—				(3.2	)			—
Depreciation and amortization		55.3				48.2				159.9				133.5
Intellectual property litigation costs (4)		25.7				23.5				73.2				65.6
(Income) loss from equity investments (5)		(0.4	)			(1.0	)			1.4				(1.0	)
Share-based compensation		43.4				39.0				127.1				113.9
Interest expense and interest income		(27.3	)			(36.6	)			(90.4	)			(85.8	)
Income tax expense		42.8				119.7				73.2				179.0
Adjusted EBITDA	$	300.1			$	314.5			$	804.9			$	693.0
GAAP net income	$	134.6			$	120.7			$	424.5			$	285.2
Amortization of intangible assets (1)		8.3				8.8				27.1				26.6
Business transition and other significant items (2)		26.0				1.1				39.4				2.9
Credits related to COVID-19 (3)		—				—				(3.2	)			—
Intellectual property litigation costs (4)		25.7				23.5				73.2				65.6
(Income) loss from equity investments (5)		(0.4	)			(1.0	)			1.4				(1.0	)
Adjustments related to taxes (6)		(14.3	)			49.7				(80.0	)			31.4
Non-GAAP net income	$	179.9			$	202.8			$	482.4			$	410.7

DexCom, Inc. Table E (Continued) Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures (In millions, except per share data) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2024				2023				2024				2023
GAAP net income	$	134.6			$	120.7			$	424.5			$	285.2
Interest expense on senior convertible notes, net of tax		2.9				3.0				8.7				9.6
GAAP net income used for diluted EPS, if-converted (7)	$	137.5			$	123.7			$	433.2			$	294.8
Non-GAAP net income	$	179.9			$	202.8			$	482.4			$	410.7
Interest expense on senior convertible notes, net of tax		1.3				1.2				3.7				3.7
Non-GAAP net income used for diluted EPS, if-converted (7)	$	181.2			$	204.0			$	486.1			$	414.4
GAAP diluted net income per share (7)	$	0.34			$	0.29			$	1.04			$	0.69
Amortization of intangible assets (1)		0.02				0.02				0.07				0.07
Business transition and other significant items (2)		0.06				—				0.10				0.01
Credits related to COVID-19 (3)		—				—				(0.01	)			—
Intellectual property litigation costs (4)		0.06				0.06				0.18				0.16
(Income) loss from equity investments (5)		—				—				—				—
Adjustments related to taxes (6)		(0.04	)			0.12				(0.20	)			0.08
Impact of adjustment to GAAP diluted shares (8)		—				0.01				—				0.01
Non-GAAP diluted net income per share (7) (9)	$	0.45			$	0.50			$	1.19			$	1.02
GAAP diluted weighted-average shares outstanding		410.2				426.8				414.7				428.3
Non-GAAP diluted weighted-average shares outstanding		402.5				407.2				407.0				407.6
Reconciliation of non-GAAP diluted weighted-average shares outstanding:
GAAP diluted weighted-average shares outstanding		410.2				426.8				414.7				428.3
Adjustment for dilutive impact of senior convertible notes due 2023 (10)		—				(11.9	)			—				(16.5	)
Adjustment for dilutive impact of senior convertible notes due 2028 (10)		(7.7	)			(7.7	)			(7.7	)			(4.2	)
Non-GAAP diluted weighted-average shares outstanding		402.5				407.2				407.0				407.6

(1)		Represents amortization of acquired intangible assets.
(2)		For the three months ended September 30, 2024, business transition and other significant items are primarily related to a non-recurring $24.6 million non-cash inventory build charge and rent for vacated office space in San Diego, California. For the nine months ended September 30, 2024, business transition and other significant items are primarily related to a non-cash inventory build charge, the divestiture of certain non-CGM assets, workforce reduction costs, and rent for vacated office space in San Diego, California. For the three and nine months ended September 30, 2023, business transition and other significant items are primarily related to rent for vacated office space in San Diego, California.
(3)		Represents a credit received related to employment of personnel during the COVID-19 pandemic.
(4)		We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as further described in the section titled “Legal Proceedings” in Dexcom’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.
(5)		Represents income and losses from equity investments.
(6)		For the three months ended September 30, 2024, tax adjustments are primarily related to the tax effect of non-GAAP adjustments. For the nine months ended September 30, 2024, tax adjustments are primarily related to the tax effect of the Verily milestone payment, non-GAAP adjustments, and excess tax benefits from share-based compensation for employees. For the three and nine months ended September 30, 2023, tax adjustments are primarily related to the tax effect of non-GAAP adjustments, including the intra-entity transfer of certain intellectual property and excess tax benefits from share-based compensation for employees.
(7)		When our senior convertible notes are dilutive on a GAAP or non-GAAP basis, net income used for calculating GAAP and non-GAAP diluted net income per share includes an interest expense add back, net of tax, under the if-converted method. In loss periods, basic and diluted net loss per share are the same since the effect of potential common shares is anti-dilutive and therefore excluded.
(8)		The adjustments are for the transition from GAAP diluted net income per share to non-GAAP diluted net income per share due to our senior convertible notes.
(9)		The sum of the non-GAAP per share components may not equal the totals due to rounding.
(10)		We adjust for the dilutive effect of our senior convertible notes when the effect is not the same on a GAAP and non-GAAP basis for a given period.

ABOUT NON-GAAP FINANCIAL MEASURES

The accompanying press release dated October 24, 2024 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, non-GAAP diluted net income per share, and non-GAAP diluted weighted average shares outstanding, as well as Adjusted EBITDA.

We report non-GAAP financial measures in addition to, and not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. We use these non-GAAP financial measures for financial and operational decision making and period-to-period comparisons. We believe that these non-GAAP financial measures provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by senior management in our financial and operational decision making. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. While we compute non-GAAP financial measures using a consistent method from quarter to quarter and year to year, we may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.

These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies.

We believe that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that these financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business.

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom’s revenue to prior periods as well as to industry peers. We exclude the following items from organic revenue:

• The effect of non-CGM revenue acquired or divested in the trailing twelve months; and
• The effect of foreign currency fluctuations

Management believes that the presentation of operating results that exclude these items provides useful supplemental information to investors and facilitates the analysis of our core operating results and comparison of operating results across reporting periods. Management believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing our past and future operating performance.

Table E reconciles the non-GAAP financial measures included in this press release to the most directly comparable financial measures prepared in accordance with GAAP.

Our policy is to exclude the following items from non-GAAP financial measures for non-GAAP gross profit, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted net income per share:

• Amortization of acquired intangible assets;
• Business transition and related costs associated with acquisition and divestiture, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third-party merger and acquisition costs, and other non-recurring significant items;
• Credits related to the employment of personnel during the COVID-19 pandemic;
• Income or loss from equity investments;
• Third-party intellectual property litigation costs in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc.;
• Litigation settlement costs;
• Gain or loss on extinguishment of debt; and
• Adjustments related to taxes for the excluded items above, as well as excess benefits or tax deficiencies from share-based compensation, and the quarterly impact of other discrete items

Adjusted EBITDA excludes non-cash operating charges for share-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, gain or loss on extinguishment of debt, income or loss from equity investments, and income tax expense or benefit. For the reasons explained above, Adjusted EBITDA also excludes business transition and other significant items, COVID-19 credits, litigation settlement costs, and intellectual property litigation costs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241024954739/en/

INVESTOR RELATIONS CONTACT:

Sean Christensen

Vice President - Finance and Investor Relations

investor-relations@dexcom.com

(858) 203-6657

MEDIA CONTACT:

James McIntosh

(619) 884-2118

Source: DexCom, Inc.

FAQ

What was DexCom's (DXCM) revenue growth in Q3 2024?

DexCom's revenue grew 2% year-over-year to $994.2 million in Q3 2024, with 3% organic growth.

What is Stelo and when did DexCom (DXCM) launch it?

Stelo is DexCom's new over-the-counter glucose biosensor for adults with prediabetes and type 2 diabetes not on insulin therapy, launched in Q3 2024 as the first OTC glucose biosensor in the U.S.

What is DexCom's (DXCM) revenue guidance for 2024?

DexCom reiterated its 2024 revenue guidance of $4.00-4.05 billion, representing 11-13% organic growth.

How much cash does DexCom (DXCM) have as of Q3 2024?

As of September 30, 2024, DexCom held $2.49 billion in cash, cash equivalents and marketable securities.